Abstract:Background: In recent years, taxanes play an important role in chemotherapy of breast cancer patients, and its response rate is about 50%. Taxanes is primarily metabolized by CYP450 in liver microsome, and it also is a substrate for P-glycoprotein (the coded product of MDR1 gene). The interindividual heterogeneity in drug-metabolizing enzymes and transporters has contributed to the variability on anti-cancer efficacy of taxanes in breast cancer patients. Several studies showed that the pharmacokinetics of taxanes was influenced by the MDR1 polymorphisms. The aim of this study is to investigate the relationship between MDR1 gene polymorphisms and taxanes-based chemotherapy responses, and provides useful information for clinical personalized medicine and prognostic judgment. Material and Methods: Genotyping of MDR1 variants was determined in the blood samples from 142 Chinese Han patients with breast cancer, by PCR-RFLP. The association of the gene polymorphisms of MDR1 C1236T at exon 12, G2677T/A at exon 21 and C3435T at exon 26 with chemotherapy responses was analyzed on the 63 patients, who received taxanes-based neoadjuvant chemotherapy [56 cases with TA (taxanes and anthracycline), 7 cases with TAC (C: cyclophosphamide)] and had the intact treatment follow-up information. Results: In the 142 breast cancer patients, the frequencies of C1236T, G2677T, G2677A and C3435T variant alleles was 70.7%,52.1%,2.5% and 46.5%, respectively, and the frequency of 3435T allele was significantly higher in comparison with that in healthy subjects (34.7%). In the 63 patients with neoadjuvant chemotherapy, the overall clinical response rate (CR+PR) to chemotherapy was 66.7%. 3435TT genotype was showed to be related to taxanes-based chemotherapy, and its efficient rate was 23.1%, significantly lower than that of patients carrying C allele (73.5%; x2 = 9.125, P=0.003). The 3 SNPs were in linkage disequilibrium, and the 4 haplotypes TTT, TGC, CGC and TTC were 90.6 % of all. The patients who carrying 2677G-3435C haplotype showed better response to chemotherapy compared with those with the other haplotypes combined (72.1% vs 40.0%;x 2 =9.125, P=0.003). The response rate of the patients with 2677T-3435T haplotype or 1236T-3435T haplotype (54.3% or 54.9%) were lower than that of the patients harboring the other haplotypes (82.4% or 91.7%;x 2 =4.128 and x 2 =4.118, P =0.042 for both) respectively, and the efficient rate of the patients with 1236T-2677T-3435T (54.3%) were also lower than that of the patients with other haplotypes combined (82.4%;x 2 =4.128, P=0.042). Conclusion: C1236T, G2677T/A and C3435T of MDR1 gene were polymorphic with different frequency in breast cancer patients. The analyses of MDR1 C3435T genotype and its haplotypes with C1236T or G2677T/A are valuable for predicting the taxanes-based chemotherapy responses in breast cancer patients, which deserve the further study. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-09-21.

Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study

Genome-wide Meta-Analyses Identifies Novel Taxane-Induced Peripheral Neuropathy-Associated Loci

P5-19-07: the Effects of ABCC2 and SLCO1B3 Single Nucleotide Polymorphisms on Docetaxel-Induced Leukopenia in Breast Cancer Patients.

Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

Relationship Between Single Nucleotide Polymorphisms and the Toxicy and Side Effects of Paclitaxel and Platinum-Based Chemotherapy in Patients with Malignant Tumors

Genetic determinants of taxane-induced peripheral neuropathy

A Single-Nucleotide Polymorphism of the Beta 2-Adrenergic Receptor Gene Can Predict Pathological Complete Response to Taxane- and Platinum-Based Neoadjuvant Chemotherapy in Breast Cancer.

Influence of single nucleotide polymorphisms in ABCB 1 , ABCG 2 and ABCC 2 on clinical outcomes to paclitaxel-platinum chemotherapy in patients with non-small-cell lung cancer

The Effect of CYP2C19*2 (rs4244285) and CYP17 (rs743572) SNPs on Adriamycin and Paclitaxel based Chemotherapy Outcomes in Breast Cancer Patients

ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer

Abstract P2-09-21: Effect of MDR1 Gene Polymorphisms and Haplotypes on Taxanes-Based Chemotherapy Responses in Chinese Han Patients with Breast Cancer

OR98 UPDATED OVERALL SURVIVAL (OS) OUTCOMES FROM THE PHASE 3 PHOEBE TRIAL OF PYROTINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER

Genetic variations that influence paclitaxel pharmacokinetics and intracellular effects that may contribute to chemotherapy-induced neuropathy: A narrative review

NeuroPredict: study of the predictive value of ABCB1 genetic polymorphisms and associated clinical factors in chronic chemotherapy-induced peripheral neuropathy (CIPN)

ABCB1 Polymorphism Predicts the Toxicity and Clinical Outcome of Lung Cancer Patients with Taxane‐based Chemotherapy

A Genome-Wide Association Study (gwas) of Docetaxel-Induced Peripheral Neuropathy in Calgb 90401 (Alliance)

Gene polymorphism and prediction of toxicity to platinum-based chemotherapy in patients with gynecologic cancer

The impact of EGFR gene polymorphisms on the response and toxicity derived from neoadjuvant chemotherapy for breast cancer.

Pharmacogenetic Discovery in CALGB (alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy

Precision Medicine in Childhood Cancer: The Influence of Genetic Polymorphisms on Vincristine-Induced Peripheral Neuropathy